Roche Wins FDA Approval For Tecentriq And Lurbinectedin Combination Cutting Risk Of Progression By 46% And Death By 27%

Benzinga · 10/03/2025 06:00
  • Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1
  • First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2
  • Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3